photo of Neda Rahmani Mehdiabadi

Neda Rahmani Mehdiabadi

Neda Rahmani Mehdiabadi

Details

Role Research Officer
Research area Stem Cell Medicine

Contact

Dr Neda Mehdiabadi is a postdoctoral researcher in the Heart Regeneration group at Murdoch Children’s Research Institute (MCRI).

Dr Mehdiabadi completed her Bachelor’s degree in Mechanical Engineering and Computer Science in 2019.

In 2020, she started her PhD in the lab of Professor Enzo Porrello and Associate Professor David Elliott, where she investigated the core networks underlying dilated cardiomyopathy (DCM).

In 2024, she transitioned into a research officer role, applying cutting-edge machine learning techniques to predict key regulatory networks disrupted in DCM.

Dr Mehdiabadi is integrating these findings with an automated, large-scale screening method developed during her PhD, which utilizes multiplexed transcriptomic profiling of patient-specific iPSC-derived cardiomyocytes to identify potential therapeutic compounds that modify the disease phenotype. Her research aims to identify critical network regulators and accelerate therapeutic target discovery.
Dr Neda Mehdiabadi is a postdoctoral researcher in the Heart Regeneration group at Murdoch Children’s Research Institute (MCRI).

Dr Mehdiabadi completed her Bachelor’s degree in Mechanical Engineering and Computer Science in 2019.

In 2020,...
Dr Neda Mehdiabadi is a postdoctoral researcher in the Heart Regeneration group at Murdoch Children’s Research Institute (MCRI).

Dr Mehdiabadi completed her Bachelor’s degree in Mechanical Engineering and Computer Science in 2019.

In 2020, she started her PhD in the lab of Professor Enzo Porrello and Associate Professor David Elliott, where she investigated the core networks underlying dilated cardiomyopathy (DCM).

In 2024, she transitioned into a research officer role, applying cutting-edge machine learning techniques to predict key regulatory networks disrupted in DCM.

Dr Mehdiabadi is integrating these findings with an automated, large-scale screening method developed during her PhD, which utilizes multiplexed transcriptomic profiling of patient-specific iPSC-derived cardiomyocytes to identify potential therapeutic compounds that modify the disease phenotype. Her research aims to identify critical network regulators and accelerate therapeutic target discovery.